Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

@article{Buse2013ExenatideOW,
  title={Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.},
  author={John B Buse and Michael A Nauck and Thomas Forst and Wayne H-H. Sheu and Sylvia K. Shenouda and Cory R. Heilmann and Byron J Hoogwerf and Aijun Gao and Marilyn K. Boardman and Mark Fineman and Lisa Porter and Guntram Schernthaner},
  journal={Lancet},
  year={2013},
  volume={381 9861},
  pages={117-24}
}
BACKGROUND Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes. We compared the efficacy and safety of exenatide once weekly with liraglutide once daily in patients with type 2 diabetes. METHODS We did a 26 week, open-label, randomised, parallel-group study at 105 sites in 19 countries between Jan 11, 2010, and Jan 17, 2011. Patients aged 18 years or older with type 2 diabetes… CONTINUE READING